Kazia Therapeutics Limited
KZIA · NASDAQ
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Market Cap | – | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -98.2% | 415,755.9% | -94.5% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -31,626.2% | -1,152.2% | -4,013,885.9% | -235,150% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -49,290.5% | -1,160.2% | -3,687,419.8% | -250,140% |
| EPS Diluted | -18.9 | -55 | -55 | -95 |
| % Growth | 65.6% | 0% | 42.1% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |